Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathway Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Multimodal Sleep Pathway for Shoulder Arthroplasty

NCT03269760
View directory record Official record
Conditions
Sleep Disturbance, Shoulder Arthritis, Arthroplasty Complications, Perioperative/Postoperative Complications
Interventions
Zolpidem
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Mirdametinib in People With Central Nervous System Tumors

NCT07539441
View directory record Official record
Conditions
Central Nervous System Tumors, Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COPD Care Pathway Among Patients With Cancer

NCT05984680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Cancer, Head and Neck Cancer
Interventions
Observational Phase 1, Observational Phase 2, Group I, Observational Phase 2, Group II, Observational Phase 3
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

NCT03434262
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

NCT05738213
View directory record Official record
Conditions
Migraine
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status
Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
11 Years to 15 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain

NCT01731782
View directory record Official record
Conditions
Colorectal Disease
Interventions
bupivacaine, normal saline placebo (for bupivacaine)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

NCT05054374
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of Pathways for Preterm Birth

NCT05246579
View directory record Official record
Conditions
Preterm Birth, Cervix; Pregnancy
Interventions
Not listed
Lead sponsor
John O'Brien, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Asthma and Obesity: Pilot Study

NCT04113746
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Better asthma self-management and incorporation of physical activity, Asthma Education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 30, 2026, 2:57 PM EDT
Withdrawn Phase 2 Interventional

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

NCT01368003
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
STA9090, STA9090 with Dutasteride
Drug
Lead sponsor
Toni Choueiri, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

NCT02160041
View directory record Official record
Conditions
Solid Tumor, Hematologic Malignancies
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 2:57 PM EDT
Completed No phase listed Observational

RNA Cloning and Visualization in Human Atherosclerosis

NCT01928095
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Control of the Circulation and VDR

NCT03513770
View directory record Official record
Conditions
Venous Distension Reflex, Blood Pressure
Interventions
Wrist-to-elbow (W-E) occlusion, ketorolac tromethamine, saline control
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting Phase 3 Interventional

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Pathways of Eicosanoid Metabolism

NCT04464070
View directory record Official record
Conditions
Metabolism of Prostaglandin D2
Interventions
niacin, aspirin, PGD2
Dietary Supplement · Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated Phase 1 Interventional

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

NCT05156905
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cirmtuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Completed No phase listed Observational

Tissue Collection From People With Cystic Fibrosis

NCT00015756
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 30, 2026, 2:57 PM EDT
Active, not recruiting Not applicable Interventional

Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)

NCT03968055
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Integration with Epic
Other
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of the Implementation of an Electronic Consultation ("eConsult") Platform

NCT02376855
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
eConsult
Other
Lead sponsor
Community Health Center, Inc.
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Migraine in Adolescents

NCT05654012
View directory record Official record
Conditions
Migraine
Interventions
MRI, Thermal Stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) efficiency, Hormonal assessment, Migraine-related measures, Neural assessments, Pubertal status
Device · Behavioral · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 13 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways

NCT02525887
View directory record Official record
Conditions
Chronic Disease, Endocrine System Disease, Cardiovascular Disease, Respiratory Tract Disease, CNS Metabolic Disorders
Interventions
Observation
Other
Lead sponsor
Bracane Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sevierville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 30, 2026, 2:57 PM EDT